Linked Life Data

14577451

Source:http://linkedlifedata.com/resource/pubmed/id/14577451

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-10-25
pubmed:abstractText
In this paper, we provide an overview of how the outcomes of the Uruguay Round affected the application of pharmaceutical intellectual property rights globally. Second, we explain how specific pharmaceutical policy tools can help developing states mitigate the worst effects of the TRIPS Agreement. Third, we put forward solutions that could be implemented by the World Bank to help overcome the divide between creating private incentives for research and development of innovative medicines and ensuring access of the poor to medicine. Fourth, we evaluate these solutions on the basis of utilitarian considerations and urge that equitable pricing is morally preferable to the other solutions.
pubmed:keyword
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
E
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1471-8731
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
KIE
pubmed:authorsComplete
Y
pubmed:pagination
27-48
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
pubmed:affiliation
Department of Philosophy and Religion, 361 Holmes Hall, Northeastern University, Boston, MA 02155-5000, USA. p.illingworth@neu.edu
pubmed:publicationType
Journal Article